non-Hodgkin lymphoma
Conditions
Interventions
Primary Prevention Group:Subcutaneous injection of 2 mg of pegfilgrastim with in 24-48 hours after chemotherapy
Sponsors
Anqing Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged = 18 years; 2. Patients with non-Hodgkin lymphoma confirmed by histopathology or immunomolecular biology, starting from the first chemotherapy cycle, using chemotherapeutic drugs that suppress bone marrow, including: a.Patients receiving high-risk FN (febrile neutropenia) chemotherapy regimens; b. Patients receiving intermediate-risk FN chemotherapy regimens and having =1 individual risk factors; c.Patients undergoing curative or adjuvant chemotherapy to ensure full dosage of the treatment. 3.ECOG (Eastern Cooperative Oncology Group) performance status = 2; 4. Life expectancy of at least 8 months; 5. Written informed consent obtained.
Exclusion criteria
Exclusion criteria: 1. Patients currently participating in other drug clinical trials; 2.Patients who have previously received short-acting or other long-acting granulocyte colony-stimulating factor (G-CSF) treatments; 3.Patients receiving intermediate-risk FN (febrile neutropenia) chemotherapy regimens without any individual risk factors; 4. Patients undergoing low-risk FN chemotherapy regimens; 5.Patients with severe cardiac impairment (left ventricular ejection fraction EF 2.5 times the upper limit of normal; if due to liver metastasis, > 5 times the upper limit of normal; kidney function tests: serum creatinine (Cr) > 2 times the upper limit of normal; 7. Pregnant or breastfeeding female patients; 8. Other conditions that the researcher considers contraindications for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Grade 3-4 Neutropenia; | — |
Countries
China
Contacts
Public ContactHaitao Xu
Hematology Department of Anqing Municipal Hospital
Outcome results
None listed